4//SEC Filing
McGrath Yvonne 4
Accession 0001209191-22-015080
CIK 0001808865other
Filed
Mar 1, 7:00 PM ET
Accepted
Mar 2, 7:59 PM ET
Size
12.9 KB
Accession
0001209191-22-015080
Insider Transaction Report
Form 4
McGrath Yvonne
Chief Scientific Officer
Transactions
- Sale
Common Stock
2022-03-01$36.76/sh−10,000$367,570→ 0 total - Exercise/Conversion
Common Stock
2022-03-01$4.24/sh+10,000$42,400→ 10,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-03-01−10,000→ 85,123 totalExercise: $4.24Exp: 2030-05-01→ Common Stock (10,000 underlying)
Footnotes (2)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.69 to $36.95, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F2]One-fourth of the shares subject to the stock option vested on May 1, 2021. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date.
Documents
Issuer
iTeos Therapeutics, Inc.
CIK 0001808865
Entity typeother
Related Parties
1- filerCIK 0001816213
Filing Metadata
- Form type
- 4
- Filed
- Mar 1, 7:00 PM ET
- Accepted
- Mar 2, 7:59 PM ET
- Size
- 12.9 KB